PMC:7195088 / 21214-21618 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"674","span":{"begin":171,"end":179},"obj":"Species"},{"id":"798","span":{"begin":130,"end":140},"obj":"Chemical"},{"id":"799","span":{"begin":299,"end":305},"obj":"Chemical"},{"id":"800","span":{"begin":368,"end":378},"obj":"Chemical"},{"id":"939","span":{"begin":192,"end":200},"obj":"Disease"},{"id":"940","span":{"begin":275,"end":280},"obj":"Disease"}],"attributes":[{"id":"A674","pred":"tao:has_database_id","subj":"674","obj":"Tax:9606"},{"id":"A798","pred":"tao:has_database_id","subj":"798","obj":"MESH:C000606551"},{"id":"A799","pred":"tao:has_database_id","subj":"799","obj":"MESH:D010100"},{"id":"A800","pred":"tao:has_database_id","subj":"800","obj":"MESH:C000606551"},{"id":"A939","pred":"tao:has_database_id","subj":"939","obj":"MESH:C000657245"},{"id":"A940","pred":"tao:has_database_id","subj":"940","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"le-blind RCT (NCT04252664, recruiting). Primary endpoint: time to clinical recovery in hours (follow-up 28 days).\n• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. Open-label RCT (NCT04252664, recruiting). Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).\n• Comparison of remdesivir vs. local standard of car"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T25","span":{"begin":275,"end":280},"obj":"Phenotype"}],"attributes":[{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"le-blind RCT (NCT04252664, recruiting). Primary endpoint: time to clinical recovery in hours (follow-up 28 days).\n• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. Open-label RCT (NCT04252664, recruiting). Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).\n• Comparison of remdesivir vs. local standard of car"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T104","span":{"begin":192,"end":200},"obj":"Disease"}],"attributes":[{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"le-blind RCT (NCT04252664, recruiting). Primary endpoint: time to clinical recovery in hours (follow-up 28 days).\n• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. Open-label RCT (NCT04252664, recruiting). Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).\n• Comparison of remdesivir vs. local standard of car"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T104","span":{"begin":207,"end":212},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"le-blind RCT (NCT04252664, recruiting). Primary endpoint: time to clinical recovery in hours (follow-up 28 days).\n• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. Open-label RCT (NCT04252664, recruiting). Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).\n• Comparison of remdesivir vs. local standard of car"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T237","span":{"begin":130,"end":140},"obj":"Chemical"},{"id":"T238","span":{"begin":207,"end":212},"obj":"Chemical"},{"id":"T239","span":{"begin":299,"end":305},"obj":"Chemical"},{"id":"T240","span":{"begin":368,"end":378},"obj":"Chemical"}],"attributes":[{"id":"A237","pred":"chebi_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A238","pred":"chebi_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A239","pred":"chebi_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A240","pred":"chebi_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"le-blind RCT (NCT04252664, recruiting). Primary endpoint: time to clinical recovery in hours (follow-up 28 days).\n• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. Open-label RCT (NCT04252664, recruiting). Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).\n• Comparison of remdesivir vs. local standard of car"}

{"project":"LitCovid-sentences","denotations":[{"id":"T150","span":{"begin":40,"end":113},"obj":"Sentence"},{"id":"T151","span":{"begin":114,"end":201},"obj":"Sentence"},{"id":"T152","span":{"begin":202,"end":243},"obj":"Sentence"},{"id":"T153","span":{"begin":244,"end":351},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"le-blind RCT (NCT04252664, recruiting). Primary endpoint: time to clinical recovery in hours (follow-up 28 days).\n• Comparison of remdesivir vs. local standard of care in patients with severe COVID-19. Open-label RCT (NCT04252664, recruiting). Primary endpoint: composite of fever normalization and oxygen saturation normalization (follow-up 14 days).\n• Comparison of remdesivir vs. local standard of car"}